Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Nature is full of untapped potential. Microbes are a proven but underused resource...
Nature is full of untapped potential. Microbes ...
Halo gives scientists and academics opportunities to connect with industry partner...
Halo gives scientists and academics opportuniti...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...
Aquestive Therapeutics is a specialty pharmaceu...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and phar...
NeoGenomics, Inc. is a high-complexity CLIA-cer...
Join the National Investor Network and get the latest information with your interests in mind.